| abstract |
This invention relates to a novel series of compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of stimulation of the human Group I metabotropic glutamate receptors, especially those designated as mGluR5. This invention also provides methods for the treatment of such disorders, as well as pharmaceutical formulations which employ the novel metabotropic glutamate receptor antagonists to which the present invention relates. |